- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Philips, Schering plan to partner in optical imaging
Philips and Schering are collaborating in breast imaging, using a fluorescent dye developed by Schering and an experimental optical scanner under construction by Philips. The two technologies will be merged as part of a phase I clinical trial that could begin some time next year.
Philips and Schering are collaborating in breast imaging, using a fluorescent dye developed by Schering and an experimental optical scanner under construction by Philips. The two technologies will be merged as part of a phase I clinical trial that could begin some time next year.
The fluorescent dye omocianine will be injected into the bloodstream, absorbing energy from a pulsed laser. The blood pool agent will then fluoresce, transmitting light back to the Philips scanner for reconstruction into images. The presence of abnormal vascular beds apparent in the images will indicate tumors, according to Philips.
A commercial device is several years away, as the safety and efficacy of the device and imaging agent must be documented to win FDA approval for marketing in the U.S. The clinical trials planned for next year will begin to provide that documentation.
In the meantime, Philips and Schering may expand their alliance to cover other imaging technologies and contrast agents that might lead to synergies, according to the companies. They have agreed to split equally all research and development costs as well as all future revenues from the contrast agents, medical equipment, and related services related to this partnership.
AI Facilitates Nearly 83 Percent Improvement in Turnaround Time for Fracture X-Rays
December 19th 2023In addition to offering a 98.5 percent sensitivity rate in diagnosing fractures on X-ray, an emerging artificial intelligence (AI) software reportedly helped reduce mean turnaround time on X-ray fracture diagnosis from 48 hours to 8.3 hours, according to new research presented at the Radiological Society of North America (RSNA) conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Can an Emerging PET Radiotracer Enhance Detection of Prostate Cancer Recurrence?
December 14th 2023The use of 68Ga-RM2 PET/MRI demonstrated a 35 percent higher sensitivity rate than MRI alone for the diagnosis of biochemical recurrence of prostate cancer, according to research recently presented at the Radiological Society of North America (RSNA) conference.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
Can AI Improve Detection of Extraprostatic Extension on MRI?
December 4th 2023Utilizing a deep learning-based AI algorithm to differentiate between diagnostic and non-diagnostic quality of prostate MRI facilitated a 10 percent higher specificity rate for diagnosing extraprostatic extension on multiparametric MRI, according to research presented at the recent RSNA conference.
Study: Regular Mammography Screening Reduces Breast Cancer Mortality Risk by More than 70 Percent
November 30th 2023Consistent adherence to the five most recent mammography screenings prior to a breast cancer diagnosis reduced breast cancer death risk by 72 percent in comparison to women who did not have the mammography screening, according to new research findings presented at the annual Radiological Society of North America (RSNA) conference.
